TKL Research is Building New Clinical Research Facility in Fair Lawn, N.J.
News Jun 20, 2013
TKL Research is constructing a new clinical research facility in Fair Lawn, N.J., that will include a 30-bed, Phase 1 unit as well as multiple, outpatient clinical examination rooms.
The new facility, which will also give the company an expanded capability for conducting the full range of dermatological safety studies for which it has a particular expertise, will join three other TKL Research clinics in northern New Jersey as part of the company’s Research Clinics Division.
In addition to its leading dermatology capabilities, TKL Research has deep expertise in the areas of gastroenterology, respiratory, endocrinology and women’s health and significant experience in global clinical studies for pharmaceutical, medical device, nutritional and consumer health care companies.
The company offers a full range of clinical trial management services, from strategy and protocol development to biostatistics, medical writing and regulatory submission.
“The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for Phase 1 clinical trials in which we have strong patient recruitment expertise,” said TKL Research President and CEO Jon C. Anderson, Ph.D.
The new facility also complements the company’s Clinical Trials Division, based in Rochelle Park, N.J., which provides a full-service capability in the clinical trial management of international, multicenter Phase 2-4 studies.
Founded more than 60 years ago, TKL Research moved its CRO operations to Rochelle Park, N.J., in 2006, and expanded its European capabilities with clinical operations in Münster, Germany, in 2010.
“These moves, as well as the construction of our new facility in Fair Lawn, will help us continue to deliver exceptional services to our clients that give them a competitive edge and accelerated enrollment,” Anderson said.
Anderson continued, “We’re able to work with sponsors and investigators to accelerate enrollment of high-quality study participants, and, through our comprehensive management services, we deliver strong expertise in a comprehensive range of CRO services over a wide geographic area.”
The TKL Research Fair Lawn facility is expected to be operational early next year.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE